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Abstract
Focus of brain tumour research is shifting towards tumour
genesis and genetics, and possible development of
individualized treatment plans. Genetic analysis shows
recurrent mutation in isocitrate dehydrogenase (IDH1)
gene in most Glioblastoma multiforme (GBM) cells. In this
review we evaluated the prognostic significance of IDH 1
mutation on the basis of published evidence. Multiple
retrospective clinical analyses correlate the presence of
IDH1 mutation in GBM with good prognostic outcomes
compared to wild-type IDH1. A systematic review
reported similar results. Based on the review of current
literature IDH1 mutation is an independent factor for
longer overall survival (OS) and progression free survival
(PFS) in GBM patients when compared to wild-type IDH1.
The prognostic significance opens up new avenues for
treatment. 
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Introduction
Glioblastoma multiforme (GBM) is the commonest
primary malignant brain tumour and carries poor
prognosis despite recent advances in management.1 A
comprehensive genetic analysis of protein codes has
found recurrent mutations in isocitrate dehydrogenase 1
(IDH1) gene in 12% of GBM.2 IDH1 catalyzes the oxidative
decarboxylation of isocitrate to ?-ketoglutarate which
protects cells in situation of oxidative stress.3 The
recurrent somatic mutation involves codon 132 of IDH1
gene on chromosome 2q33 and is implicated in
determining the prognosis.2 Herein we have reviewed the
evidence on the effect of IDH 1 mutation on the survival
of patients with GBM. 
Review of Evidence
Frequency of IDH1 mutation was first reported by Yan et
al., in 2009 when they extracted DNA from primary brain
tumour and xenografts, and from patient-matched
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Figure-1: a) Pre-operative MRI TIWI with contrast showing the typical location of a
GBM with IDH1 mutation. b) Post-operative MRI T1WI with contrast of the same
patient showing gross total resection.
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normal blood lymphocytes.4 The sequence of IDH1 gene
was determined and mutation was reported in majority of
the malignant gliomas. Bleeker et al., in 2010 used DNA
samples from a set of frozen GBM specimens, and
analyzed for enzyme activity and survival.5 They reported
a significant increase in overall survival for both primary
and secondary GBM in patients with IDH1 mutation. After
correction for age, Karnofsky Performance Status (KPS),
extent of surgery, received dosage of radiotherapy,
additional chemotherapy or treatment other than
radiotherapy, mutational status of IDH1 was reported as
an independent factor for OS.
In 2011 Song Tao et al.,6 reported 69.6% IDH1 mutation in
genomic DNA extracted from formalin-fixed and paraffin-
embedded GBM. All clinical features of these patients
were retrospectively analyzed and it was concluded that
patients with IDH1 mutation had longer PFS (Hazards
Regression HR = 0.110, P < 0.001).6 In 2012, Yan et al.,7 also
reported significantly longer PFS for GBM patients with
IDH1 mutation compared to wild-type IDH1. (497.0±267.8
days versus 342.3±261.6, p= 0.026). In 2013, Cheng et al.,8
reported via a meta-analysis that the IDH1 mutation has a
significant association with improved survival outcomes
in GBM patients compared to wild-type IDH1 (HR= 0.45,
95% CI, 0.29-0.69, P <0.001). They included studies
providing HR from multivariate analyses by adjusting for
confounding factors that were more accurate than the
unadjusted HR. The meta-analysis hence provides strong
evidence for IDH1 mutation as an independent
prognostic factor in improving survival in GBM patients.
In 2014, Polivka et al.,9 assessed IDH1 mutation by RT-PCR
(Reverse Transcriptase- Polymerase Chain Reaction) in
GBM specimens and correlated it with the OS and PFS.
They reported longer OS, (270 versus 130 days; P < 0.024)
and PFS (136 versus 51 days; p< 0.021) in patients with
IDH1 mutation compared to wild-type IDH1.
In 2016, Mandel et al.10 analyzed their institutional data
and found statistically significant improvement in median
OS in patients with mutated IDH1 compared to wild-type
IDH1 (83 versus 22 months; p < 0.0001). IDH1 mutation
remained a significant prognostic marker in multivariate
analysis (p 0.0005).
Conclusion
Review of evidence identifies the prognostic significance
of IDH1 mutation in GBM. Multiple studies report IDH1
mutation as a significant, independent factor for
predicting longer overall survival and progression free
survival in patients with GBM. The information can help in
treatment planning, prognostication and counseling, and
also opens new avenues for research.
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